PTGX - Protagonist Therapeutics, Inc
IEX Last Trade
39.525
0.215 0.544%
Share volume: 17,775
Last Updated: Thu 26 Dec 2024 08:29:46 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$39.31
0.22
0.55%
Fundamental analysis
22%
Profitability
25%
Dept financing
9%
Liquidity
50%
Performance
15%
Performance
5 Days
-3.20%
1 Month
-12.34%
3 Months
-12.53%
6 Months
23.74%
1 Year
70.72%
2 Year
289.11%
Key data
Stock price
$39.52
DAY RANGE
$38.90 - $39.77
52 WEEK RANGE
$22.79 - $48.89
52 WEEK CHANGE
$69.91
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Dinesh V. Patel
Region: US
Website: protagonist-inc.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: protagonist-inc.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.
Recent news